Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2375-2381

  McSharry, James J ^a   Weng, Qingmei ^a   Brown, Ashley ^a   Kulawy, Robert ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; BETA GALACTOSIDASE; BETA GALACTOSIDASE ALPHA 2,6 SIALYLTRANSFERASE 1; GENE PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EXPOSURE; DRUG HALF LIFE; HOLLOW FIBER; IN VITRO STUDY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VIROGENESIS; VIRUS HEMAGGLUTINATION; VIRUS INFECTIVITY; VIRUS PLAQUE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLUENZA A VIRUS, H3N2 SUBTYPE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; OSELTAMIVIR;

EID: 67049145613     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00167-09     Document Type: Article

References (34)

1. Baccam, P., C. Beauchemin, C. A. Macken, F. G. Hayden, and A. S. Perelson. 2006. Kinetics of influenza A virus infection. J. Virol. 80:7590-7599. (Pubitemid 44092580)
2. Bantia, S., C. S. Arnold, C. D. Parker, R. Upshaw, and P. Chand. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir. Res. 69:39-45.
3. Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167.
4. Baz, M., Y. Abed, B. Nehme, and G. Boivin. 2009. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. Antimicrob. Agent Chemother. 53:791-793.
5. Belshe, R. B. 2005. The origins of pandemic influenza: lessons from the 1918 virus. N. Engl. J. Med. 353:2209-2211.
6. Belshe, R. B., M. H. Smith, C. B. Hall, R. Betts, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1508-1512. (Pubitemid 18133166)
7. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow fiber pharmacodynamic model system correlates with results of dose ranging clinical studies. Antimicrob. Agent Chemother. 38:1386-1391.
8. Bilello, J. A., P. A. Bilello, J. J. Kort, M. N. Dudley, J. Leonard, and G. L. Drusano. 1995. Efficacy of constant infusion of A77003, an inhibitor of the HIV protease, in limiting acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 39:2523-2527.
9. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during 2005-2006 influenza season in the United States. JAMA 295:891-894. (Pubitemid 43295823)
10. Chand, P., S. Banita, P. L. Kotian, Y. El-Kattan, T. H. Lin, and Y. S. Babu. 2005. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg. Med. Chem. 13:4071-4077.
11. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
12. Deyde, V. M., T. Nguyen, R. A. Bright, A. Balish, B. Shu, S. Lindstrom, A. I. Klimov, and L. V. Gubareva. 2009. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using pyrosequencing method. Antimicrobial. Agents Chemother. 53:1039-1047.
13. Douglas, W. R. 1975. Influenza in man, p. 397-446. In E. D. Kilbourne (ed.), Influenza viruses and influenza. Academic Press, New York, NY.
14. Drusano, G. L., P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDowell, A. Bye, and J. A. Bilello. 2002. Pharmacodynamics of abacavir in an in vitro hollow fiber model system. Antimicrob. Agents Chemother. 46:464-470.
15. Drusano, G. L., J. A. Bilello, S. L. Preston, E. Omara, S. Kaul, S. Schnittman, and R. Echols. 2001. Hollow fiber unit evaluation of a new human immunodeficiency virus (HIV)-1 protease inhibitor, BMS232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183:1126-1129.
16. Drusano, G. L., K. H. P. Moore, J. P. Kleim, W. Prince, and A. Bye. 2002. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:913-916.
17. Drusano, G. L., S. L. Preston, D. Smee, K. Bush, K. Bailey, and R. W. Sidwell. 2001. Pharmacodynamic evealuation of RWJ 270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza, predicts efficacy for once-daily dosing. Antimicrob. Agents Chemother. 45:2115-2118.
18. Hatakeyama, S., Y. Sakai-Tagawa, M. Kiso, H. Goto, C. Kwakami, K. Mitamura, N. Sugaya, Y. Suzuki, and Y. Kawaoka. 2005. Enhanced expression of an α2,6-linked sialic acid on MDCK cells improved isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43:4139-4146.
19. Hayden, F. G. 2006. Antiviral resistance in influenza viruses: implications for management and pandemic response. N. Engl. J. Med. 354:785-788.
20. Hayden, F. G., K. M. Cote, and R. G. Douglas, Jr. 1980. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrobial. Agents Chemother. 17:865-870.
21. Hayden, F. G., L. V. Gubareva, A. S. Monto, T. C. Klein, M. J. Elliott, J. M. Hammond, S. J. Sharp, and M. J. Ossi for the Zanamivir Family Study Group. 2000. Inhaled zanamivir for the prevention of influenza in families. N. Engl. J. Med. 343:1282-1289.
22. Holodniy, M., S. R. Penzak, T. M. Straight, R. T. Davey, K. K. Lee, M. B. Goetz, D. W. Raisch, F. Cunningham, E. T. Lin, N. Olivo, and L. R. Deyton. 2008. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob. Agent Chemother. 52:3013-3021.
23. Ison, M. G., V. P. Mishin, T. J. Braciale, F. G. Hayden, and L. V. Gubareva. 2006. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 193:765-772.
24. Kati, W. M., D. Montgomery, R. Carrick, L. Gubareva, C. Maring, K. McDaniel, K. Steffy, A. Molla, F. Hayden, D. Kempf, and W. Kohlbrenner. 2002. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agent Chemother. 46:1014-1024.
25. Kilbourne, E. D. 2006. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12:9-14.
26. McSharry, J. J., M. R. Deziel, K. Zager, Q. Weng, and G. L. Drusano. 2009. Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow fiber infection model system. Antimicrob. Agents Chemother. 53:129-135.
27. McSharry, J. J., A. C. McDonough, B. A. Olson, and G. L. Drusano. 2004. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin. Diagn. Lab. Immunol. 11:21-28.
28. Molla, A., W. Kati, R. Carrick, K. Steffy, Y. Shi, D. Montgomery, N. Gusick, V. S. Stoll, K. D. Stewart, T. I. Ng, C. Maring, D. J. Kempf, and W. Kohlbrenner. 2002. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 76:5380-5386.
29. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373.
30. Moscona, A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
31. Preston, S. L., P. J. Piliero, J. A. Bilello, D. S. Stein, W. T. Symonds, and G. L. Drusano. 2003. In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrob. Agents Chemother. 47:3393-3399.
32. Sidwell, R. W., and D. F. Smee. 2000. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antivir. Res. 48:1-16.
33. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186. (Pubitemid 36068705)
34. Treanor, J. J., F. G. Hayden, P. S. Vrooman, R. Barbarash, R. Bettis, D. Riff, S. Singh, N. Kinnersley, P. Ward, and R. G. Mills for the US Oral Neuraminidase Study Group. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized, controlled trial. JAMA 283:1016-1024.